Description

BPC 157 is a stable gastric pentadecapeptide and a partial sequence of the human gastric juice protein BPC. BPC 157 is an anti-ulcer peptidergic agent with no reported toxicity. BPC 157 links inflammatory bowel disease and multiple sclerosis[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C62H98N16O22—-[1]Sikiric P, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632.|[2]Klicek R, et al. Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. J Physiol Pharmacol. 2013;64(5):597-612.–137525-51-0–1419.54–99.86–O=C([C@H]1N(CCC1)C([C@H](CCC(O)=O)NC(CN)=O)=O)N2[C@@H](CCC2)C(N3[C@@H](CCC3)C(NCC(N[C@@H](CCCCN)C(N4[C@@H](CCC4)C(N[C@@H](C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(NCC(N[C@@H](CC(C)C)C(N[C@H](C(O)=O)C(C)C)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O–Inflammation/Immunology–DMSO : 50 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL–Endogenous Metabolite—-Metabolic Enzyme/Protease–Peptides